WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Overcoming Challenges in Car T-Cell Therapy: Addressing Toxicities and Enhancing Accessibility

Uche Philip[1] and Umobit Ini-obong Deborah[2]

[1]Department of Hematology and Oncology, Union Hospital affiliated to Fujian Medical University, Fujian Medical University
[2]Department of Biology, Georgia State University.
DOI : https://doi.org/10.55248/gengpi.5.1124.3327

ABSTRACT

Chimeric Antigen Receptor [CAR] T-cell therapy represents a groundbreaking advancement in immunotherapy, offering significant potential for treating hematologic malignancies. Despite its transformative success, the therapy is accompanied by substantial challenges that hinder its broader application. Severe toxicities, including cytokine release syndrome [CRS] and immune effector cell-associated neurotoxicity syndrome [ICANS], pose significant risks to patients, necessitating careful monitoring and management. Furthermore, the high cost of treatment and limited manufacturing scalability have created barriers to accessibility, restricting the therapy's availability to a narrow subset of patients. This review examines these critical challenges and explores strategies to mitigate them. Advances in toxicity management, such as the use of IL-6 inhibitors like tocilizumab and corticosteroids, have improved patient outcomes by reducing the severity of CRS and ICANS. Efforts to refine CAR T-cell design, including incorporating safety switches and modulating activation domains, are further enhancing the therapy's safety profile. On the accessibility front, innovations in automated manufacturing and the development of allogeneic ["off-the-shelf"] CAR T-cell products are reducing production costs and time, paving the way for more scalable solutions. Additionally, this article highlights initiatives to improve equity in CAR T-cell therapy, including expanded insurance coverage, partnerships with non-profit organizations, and clinical trials targeting underrepresented populations. By addressing these challenges, the field aims to balance the promise of CAR T-cell therapy with practical solutions for delivering it to a wider patient population. The findings underscore the need for collaborative efforts among researchers, clinicians, policymakers, and industry stakeholders to overcome these barriers, ultimately transforming CAR T-cell therapy from a niche treatment into a widely accessible standard of care.

Keywords: CAR T-Cell Therapy; CRS; Neurotoxicity; Treatment; Accessibility; Cost Reduction Strategies; Immunotherapy Advancements

1. INTRODUCTION

1.1 Overview of CAR T-Cell Therapy

Chimeric Antigen Receptor [CAR] T-cell therapy represents a transformative approach in immunotherapy, leveraging a patient's immune system to identify and eliminate cancer cells [1]. The process involves isolating T-cells from a patient's blood, genetically engineering them to express a CAR—designed to recognize specific tumour antigens—and reinfusing them into the patient. This therapy provides a targeted mechanism for immune-mediated cancer destruction, significantly enhancing therapeutic efficacy [2].

CAR T-cell therapy has demonstrated remarkable success in treating hematologic malignancies, including relapsed or refractory B-cell acute lymphoblastic leukemia [B-ALL] and diffuse large B-cell lymphoma [DLBCL] [4]. Clinical trials report durable remissions in up to 80% of patients, even in cases where conventional treatments have failed. This has led to FDA approval of therapies like tisagenlecleucel and axicabtagene ciloleucel, revolutionizing the landscape of hematologic cancer care [2].

However, extending this success to solid tumours remains challenging due to the complexity of the tumour microenvironment. Solid tumours often feature physical barriers that limit T-cell infiltration, heterogeneous antigen expression, and immunosuppressive factors, such as regulatory T-cells and myeloid-derived suppressor cells, which inhibit CAR T-cell activity [3]. Advances in CAR T-cell engineering, including dual-targeting CARs and strategies to overcome immune evasion, offer hope for expanding the therapy's utility beyond hematologic cancers [4]. CAR T-cell therapy represents a significant breakthrough, offering curative potential in previously incurable cancers. Its success in hematologic malignancies underscores its transformative impact, while ongoing innovations aim to broaden its applicability to more complex tumour types [9].

1.2 Challenges in CAR T-Cell Therapy

Despite its success, CAR T-cell therapy faces significant challenges that hinder its broader implementation. The most critical issue is **toxicity**, particularly CRS and neurotoxicity. CRS results from excessive immune activation and is characterized by fever, hypotension, and systemic

inflammation [7]. Severe cases can lead to organ dysfunction or death, requiring prompt management with tocilizumab or corticosteroids, which may diminish the therapy's efficacy. Neurotoxicity, another severe complication, can manifest as confusion, seizures, or cerebral edema, further complicating treatment [5].

Accessibility is another major barrier. The manufacturing process for CAR T-cell therapy is complex, involving T-cell collection, genetic engineering, and reinfusion. This individualized approach drives costs to over $400,000 per patient, making it financially inaccessible for many healthcare systems [5]. Additionally, the need for specialized facilities and trained personnel restricts its availability, particularly in low-resource settings [6].

Challenges with the tumour microenvironment in solid tumours also limit the therapy's effectiveness. Immunosuppressive factors, physical barriers, and antigen heterogeneity complicate CAR T-cell infiltration and persistence [8]. Overcoming these challenges requires engineering innovations, such as modifying CAR constructs to resist immune suppression and optimizing their targeting capabilities [7].

To ensure broader adoption, addressing these challenges is essential. Advances in manufacturing efficiency, strategies to mitigate toxicity, and efforts to reduce costs are critical for expanding the reach and impact of CAR T-cell therapy [6].

1.3 Scope and Objectives

This article explores the current challenges and future directions of CAR T-cell therapy, with a focus on overcoming barriers that limit its broader adoption. The primary objectives are to identify strategies for addressing toxicity, reducing costs, and enhancing accessibility, ensuring that this transformative therapy reaches more patients worldwide.

Addressing Toxicities: Improving the safety profile of CAR T-cell therapy is paramount. Strategies such as incorporating safety switches, optimizing CAR designs, and using biomarkers to identify patients at risk for severe toxicities will be discussed [5]. These approaches aim to balance therapeutic efficacy with patient safety, mitigating life-threatening complications like CRS and neurotoxicity [8].

Reducing Costs: The high cost of CAR T-cell therapy is a significant barrier to widespread adoption. Innovations in manufacturing processes, such as the development of off-the-shelf CAR T-cells, automated production platforms, and enhanced supply chain efficiency, have the potential to lower costs significantly. This section will explore these technological advances and their implications for cost reduction [9].

Enhancing Accessibility: Expanding the global reach of CAR T-cell therapy requires addressing disparities in healthcare infrastructure and treatment availability [7]. This article will discuss efforts to increase the number of certified treatment centres, streamline regulatory processes, and foster collaborations among academia, industry, and policymakers to ensure equitable access to this life-saving therapy [10]. By addressing these critical issues, the article aims to highlight actionable solutions that can drive the future success and accessibility of CAR T-cell therapy.

2. UNDERSTANDING TOXICITIES IN CAR T-CELL THERAPY

2.1 CRS

CRS is a life-threatening toxicity associated with CAR T-cell therapy. It results from the excessive activation of T-cells, which leads to a surge in pro-inflammatory cytokines, including interleukin-6 [IL-6], interferon-gamma [IFN-γ], and tumour necrosis factor-alpha [TNF-α]. This cascade of immune activation creates a hyperinflammatory state, causing systemic symptoms and organ dysfunction [11].

Pathophysiology of CRS

The pathophysiology of CRS begins with CAR T-cell engagement with tumour antigens, which triggers T-cell activation and proliferation. This activation releases cytokines that recruit and activate other immune cells, including macrophages and monocytes, amplifying the inflammatory response [9]. The release of IL-6, in particular, plays a pivotal role in CRS, as it drives fever, vascular leakage, and hypotension [2]. In severe cases, cytokine overload can lead to multiorgan failure, including respiratory and cardiovascular collapse.

Symptoms and Grading of CRS Severity

CRS symptoms range from mild flu-like manifestations to severe organ dysfunction. Common symptoms include fever, hypotension, tachycardia, hypoxia, and elevated liver enzymes [12]. The **American Society for Transplantation and Cellular Therapy [ASTCT]** has developed a standardized grading system for CRS:

1. **Grade 1:** Mild symptoms, no organ dysfunction. Managed with supportive care.
2. **Grade 2:** Low-grade hypotension responsive to fluids or mild hypoxia requiring low-flow oxygen.
3. **Grade 3:** More severe hypotension requiring vasopressors and/or hypoxia necessitating high-flow oxygen.
4. **Grade 4:** Life-threatening symptoms, including ventilator-dependent respiratory failure and multiorgan dysfunction [3].

Current Management Strategies

Management of CRS focuses on mitigating the inflammatory response while preserving CAR T-cell activity:

1. **IL-6 Inhibitors:** Tocilizumab, an anti-IL-6 receptor monoclonal antibody, is the frontline therapy for CRS. It rapidly reduces inflammation and alleviates symptoms, particularly fever and hypotension [14].
2. **Corticosteroids:** For severe cases, corticosteroids such as dexamethasone or methylprednisolone are used to suppress immune activity. However, their use is cautious to avoid impairing CAR T-cell efficacy [9].
3. **Supportive Care:** Includes antipyretics, oxygen supplementation, and vasopressors for hemodynamic support. Monitoring in an intensive care unit is often necessary for severe CRS cases [6].

Table 1 CRS Grading and Management Strategies

Grade	Symptoms	Management
Grade 1	Fever, mild flu-like symptoms	Supportive care, antipyretics
Grade 2	Hypotension responsive to fluids, mild hypoxia	Tocilizumab, supportive care
Grade 3	Vasopressor-dependent hypotension, hypoxia	Tocilizumab, corticosteroids, ICU care
Grade 4	Multiorgan failure, ventilator support	Tocilizumab, high-dose corticosteroids, ICU

2.2 Immune Effector Cell-Associated Neurotoxicity Syndrome [ICANS]

ICANS is another critical toxicity of CAR T-cell therapy, characterized by neurological symptoms ranging from mild confusion to severe cerebral edema. ICANS often co-occurs with CRS but can also manifest independently [7].

Mechanisms of ICANS Development

The exact pathophysiology of ICANS remains incompletely understood, but two key mechanisms are implicated:

1. **Blood-Brain Barrier Disruption:** Elevated levels of cytokines, particularly IL-6 and IFN-γ, increase vascular permeability, disrupting the blood-brain barrier. This allows cytokines and immune cells to infiltrate the central nervous system CNS, triggering neuroinflammation.
2. **Cytokine Effects on Neurons:** Direct exposure of CNS tissue to cytokines causes neuronal damage, astrocyte activation, and microglial proliferation, contributing to ICANS symptoms [8].

Clinical Presentation and Grading

ICANS symptoms progress along a continuum, from mild to severe. Early manifestations include headache, confusion, and word-finding difficulty. As the condition worsens, patients may experience seizures, motor weakness, and coma. The **ASTCT grading system** categorizes ICANS as follows:

i. **Grade 1:** Mild symptoms, such as confusion or mild language impairment.
ii. **Grade 2:** Moderate symptoms, including moderate language dysfunction or disorientation.
iii. **Grade 3:** Severe symptoms requiring interventions such as seizures or significant cognitive impairment.
iv. **Grade 4:** Life-threatening symptoms, including cerebral edema, coma, and critical neurologic impairment [9].

Treatment Approaches and Monitoring Protocols

The treatment of ICANS focuses on controlling neuroinflammation and preventing irreversible CNS damage:

1. **Corticosteroids:** High-dose dexamethasone is the primary treatment for ICANS. It effectively reduces CNS inflammation and alleviates symptoms.
2. **Supportive Therapy:** Includes anticonvulsants for seizure management and osmotic agents like mannitol for intracranial pressure reduction.
3. **Monitoring Protocols:** Continuous neurologic assessment using tools like the **Immune Effector Cell-Associated Encephalopathy [ICE]** score is critical for early detection and intervention. Routine imaging, such as MRI or CT, may be employed to monitor cerebral edema [10].



Figure 1 Chart showing Timeline of ICANS Development and Resolution A visual representation showing symptom progression from early neurologic signs to peak severity and subsequent resolution with treatment.

2.3 Other Adverse Effects

In addition to CRS and ICANS, CAR T-cell therapy is associated with other significant adverse effects, including infections, cytopenias, and organ dysfunction.

Infections Due to Immunosuppression

CAR T-cell therapy often leads to prolonged immunosuppression, increasing susceptibility to opportunistic infections. Neutropenia, a common side effect of CAR T-cell therapy, further compromises the immune system, leaving patients vulnerable to bacterial, viral, and fungal infections. Prophylactic antimicrobials and close monitoring are essential to reduce infection-related morbidity [11].

Cytopenias

Cytopenias, particularly neutropenia, thrombocytopenia, and anemia, are common after CAR T-cell infusion. These cytopenias result from lymphodepleting chemotherapy, bone marrow suppression, and immune-mediated effects. Persistent cytopenias can delay subsequent treatments and increase the risk of bleeding and infections. Management strategies include growth factor support, such as granulocyte colony-stimulating factor [G-CSF], and transfusions when necessary [12].

Organ Dysfunction

Organ dysfunction, including liver toxicity, renal impairment, and cardiac dysfunction, can occur as secondary effects of CRS or due to direct immune-mediated damage. Hepatotoxicity is often marked by elevated liver enzymes, while renal toxicity can result from cytokine-induced hypoperfusion [11]. Early detection and supportive care, such as fluid management and hemodynamic stabilization, are vital for minimizing complications [13].

These adverse effects underscore the need for comprehensive monitoring and multidisciplinary management to ensure the safety and efficacy of CAR T-cell therapy.

3. ENHANCING THE SAFETY OF CAR T-CELL THERAPY

3.1 Next-Generation CAR Designs

The development of next-generation CAR T-cell designs is central to improving the safety profile of this transformative therapy. By incorporating novel mechanisms and engineering strategies, researchers aim to reduce off-target effects, enhance tumour specificity, and provide clinicians with better control over CAR T-cell activity.

Incorporating Safety Switches

One key innovation is the incorporation of **safety switches**, which provide clinicians with the ability to deactivate CAR T-cells in the event of severe toxicity. **Suicide genes**, such as inducible caspase-9 [iC9], are engineered into CAR T-cells, allowing their rapid elimination upon administration of a specific drug. This approach has demonstrated effectiveness in preclinical models, where severe toxicities were mitigated without compromising the therapy's efficacy [15].

Another safety mechanism involves **on/off switches**, which temporarily halt CAR T-cell activity when toxicities arise. These switches use small-molecule drugs to modulate CAR T-cell function, enabling reversible control [21]. For example, studies have explored incorporating synthetic receptors that activate only in the presence of specific molecules, preventing unintended immune responses [16].

Dual-Targeting CAR T-Cells

Dual-targeting CAR T-cells represent another promising strategy to enhance safety. By requiring two tumour-specific antigens for activation, dual-targeting CARs minimize off-tumour effects and reduce the risk of attacking healthy tissues [15]. For instance, bispecific CARs targeting CD19 and CD22 have shown improved safety profiles in B-cell malignancies while maintaining therapeutic efficacy [17].

Additionally, next-generation CARs are being designed to incorporate **sensing circuits** that detect the tumour microenvironment's specific conditions, such as hypoxia or pH, ensuring that CAR T-cells activate only in targeted regions. These advances significantly enhance the precision and safety of CAR T-cell therapy [18].

3.2 Optimizing Dosing and Delivery

Dosing and delivery optimization are crucial strategies for reducing the risk of severe toxicities associated with CAR T-cell therapy. Determining the appropriate cell dose and delivery method can significantly mitigate adverse effects while maintaining therapeutic efficacy.

Optimizing Cell Dose

One of the most effective strategies for reducing toxicities, particularly CRS and ICANS, is optimizing the cell dose administered to patients. Studies have demonstrated that lower doses of CAR T-cells can achieve effective tumour eradication with reduced toxicity risks, especially in patients with smaller tumour burdens [19].

Fractionated dosing, where CAR T-cells are administered in multiple smaller infusions rather than a single large dose, further enhances safety. This approach allows clinicians to monitor for early signs of toxicity and adjust subsequent doses accordingly, reducing the likelihood of severe immune activation [20].

Regional Delivery

Regional delivery of CAR T-cells is another emerging strategy to minimize systemic toxicities. By infusing CAR T-cells directly into the tumour site or surrounding regions, clinicians can localize the immune response, reducing off-target effects. For example, intratumoural delivery in solid tumours has shown promise in preclinical models, as it concentrates therapeutic activity in the tumour microenvironment while sparing healthy tissues [21].

Additionally, advances in delivery systems, such as biodegradable scaffolds and nanoparticle carriers, are being explored to control CAR T-cell distribution and activity more precisely [14]. These innovations aim to enhance the safety and effectiveness of CAR T-cell therapy across diverse cancer types [22].

3.3 Improving Monitoring and Early Intervention

Improved monitoring and early intervention are critical for enhancing the safety profile of CAR T-cell therapy. By leveraging real-time biomarkers and advanced technologies, clinicians can detect and manage toxicities at their earliest stages.

Real-Time Biomarkers

The identification and use of real-time biomarkers enable clinicians to predict and monitor toxicities more effectively. Biomarkers such as serum levels of IL-6, C-reactive protein [CRP], and ferritin are well-established indicators of CRS severity. Regular monitoring of these markers allows for early identification of at-risk patients and prompt initiation of therapeutic interventions [23].

Emerging biomarkers, such as neurofilament light chain [NFL] for detecting neurotoxicity, are under investigation to improve the prediction of ICANS. Incorporating these biomarkers into routine clinical practice could significantly enhance the safety of CAR T-cell therapy by enabling preemptive management [24].

AI-Based Monitoring Tools

Artificial intelligence [AI] is transforming how clinicians monitor and respond to CAR T-cell therapy-related toxicities. AI-based tools analyze vast datasets from electronic health records, wearable devices, and laboratory results to identify patterns indicative of early toxicity. Machine learning algorithms can predict the onset of CRS or ICANS with high accuracy, providing alerts to clinicians for timely intervention [25].

These tools also facilitate personalized care by integrating patient-specific factors, such as age, comorbidities, and tumour burden, into risk assessment models. The integration of AI-based monitoring systems into clinical workflows is expected to improve outcomes by enabling real-time decision-making and reducing the incidence of severe toxicities.

4. ADDRESSING ACCESSIBILITY CHALLENGES

4.1 Cost of CAR T-Cell Therapy

The **cost of CAR T-cell therapy** is one of the primary barriers to patient accessibility. The financial burden stems from the complex nature of the treatment, including manufacturing, hospitalization, and supportive care, making it one of the most expensive therapies in oncology.

Breakdown of Treatment Costs

1. **Manufacturing Costs**: The process of creating autologous CAR T-cells involves isolating a patient's T-cells, genetically engineering them to express chimeric antigen receptors, expanding them in vitro, and reinfusing them into the patient. This labour-intensive, individualized process accounts for a significant portion of the therapy's total cost, with estimates ranging from $150,000 to $250,000 per treatment [15].
2. **Hospitalization**: Patients receiving CAR T-cell therapy often require prolonged hospital stays, particularly for monitoring and managing toxicities such as CRS and ICANS. Intensive care unit [ICU] stays for severe toxicities further escalate costs, averaging $30,000 to $50,000 per patient [16].
3. **Supportive Care**: Supportive measures, including the administration of immunosuppressive drugs [e.g., tocilizumab, corticosteroids], antimicrobial prophylaxis, and transfusions, add to the financial burden. These costs vary depending on the severity of toxicities but are estimated to contribute an additional $10,000 to $20,000 to overall expenses [17].

Financial Burden on Patients and Healthcare Systems

For patients, the out-of-pocket costs can be overwhelming, particularly in countries without comprehensive health insurance. Even in well-funded healthcare systems, the high cost of CAR T-cell therapy strains budgets and challenges policymakers to balance innovation with financial sustainability. Health insurance companies and government programs often require extensive justification for reimbursement, leading to delays in treatment for eligible patients [18].

Strategies to address these financial barriers include value-based pricing models, outcomes-based reimbursement plans, and government subsidies. For example, outcomes-based agreements between manufacturers and payers tie payments to the therapy's clinical success, reducing the risk for healthcare systems while ensuring access for patients [19].

4.2 Manufacturing Bottlenecks

Manufacturing bottlenecks represent a significant barrier to the accessibility of CAR T-cell therapy. The current reliance on autologous CAR T-cell production, where T-cells are derived from each patient, introduces challenges related to time, cost, and scalability.

Challenges in Autologous CAR T-Cell Production

1. **Time-Intensive Process**: The production of autologous CAR T-cells typically takes 2 to 4 weeks, during which the patient's disease may progress. This delay limits the therapy's applicability in aggressive cancers such as refractory leukemia [20].
2. **Resource Intensity**: The need for highly specialized facilities, skilled personnel, and stringent quality control measures increases production costs and restricts scalability. Small manufacturing batches tailored to individual patients further exacerbate inefficiencies [21].
3. **Variability in Quality**: Autologous CAR T-cell products are subject to variations in the quality of the starting material [patient-derived T-cells], which can impact the therapy's efficacy and safety [22].

Innovations in Manufacturing

1. **Automation**: The use of automated manufacturing platforms streamlines the production process, reducing labor requirements and minimizing human error. These systems enable consistent quality and faster production times, making CAR T-cell therapy more accessible [23].
2. **Allogeneic ["Off-the-Shelf"] CAR T-Cells**: Allogeneic CAR T-cells, derived from healthy donors, offer a promising alternative to autologous therapies. These "off-the-shelf" products are manufactured in advance, allowing for immediate availability. They also reduce production costs significantly due to economies of scale [24].
3. **Gene Editing Technologies**: Advances in CRISPR-Cas9 and other gene editing tools enable the development of allogeneic CAR T-cells with enhanced safety and efficacy. For example, gene editing can eliminate the risk of graft-versus-host disease [GVHD], a potential complication of donor-derived cells, by knocking out endogenous T-cell receptors [25].

While these innovations hold great promise, regulatory challenges and the need for further clinical validation remain hurdles to widespread adoption.

4.3 Expanding Treatment Centres

The limited availability of specialized **CAR T-cell therapy centres** further restricts patient access. These centres require advanced infrastructure, trained personnel, and regulatory compliance, leading to geographic disparities in treatment availability.

Limited Availability of Specialized Centres

CAR T-cell therapy is currently offered at a limited number of accredited centres, predominantly located in urban or high-resource areas. Patients from rural or underserved regions often face significant challenges in accessing these facilities, including travel expenses, time away from work, and the need for temporary relocation. This lack of accessibility exacerbates health inequities and limits the therapy's reach [26].

Training Programs and Infrastructure Development

To expand access, efforts are underway to increase the number of treatment centres and enhance their capacity. Key strategies include:

1. **Training Programs**: Establishing comprehensive training programs for healthcare professionals is essential to ensure safe and effective administration of CAR T-cell therapy. These programs focus on toxicity management, patient monitoring, and handling of CAR T-cell products [27].
2. **Infrastructure Development**: Expanding existing hospitals and building new facilities equipped to administer CAR T-cell therapy can broaden geographic coverage. Partnerships between academic institutions, private companies, and government agencies are critical for funding and resource allocation [28].
3. **Telemedicine Integration**: Leveraging telemedicine for follow-up care and toxicity monitoring reduces the burden on patients and minimizes the need for frequent visits to treatment centres. This approach enhances patient convenience while maintaining safety standards [29].

Table 2 Comparison of Autologous vs. Allogeneic CAR T-Cell Therapy

Aspect	**Autologous CAR T-Cells**	**Allogeneic CAR T-Cells**
Source of T-Cells	Patient-derived	Healthy donor-derived
Manufacturing Time	2–4 weeks	Pre-manufactured, immediately available
Cost per Treatment	$150,000–$250,000	~$50,000–$100,000
Scalability	Limited by individualized production	High due to mass production
Risk of GVHD	None	Mitigated by gene editing
Efficacy in Trials	High	Promising but under clinical investigation

5. INNOVATIONS IN CAR T-CELL THERAPY

5.1 Expanding Targets Beyond Hematologic Malignancies

CAR T-cell therapy has achieved significant success in treating hematologic malignancies, but expanding its application to **solid tumours** remains a formidable challenge. Advances in CAR T-cell engineering and understanding of tumour biology are driving progress in this area.

Challenges in Solid Tumour Applications

1. **Tumour Microenvironment [TME]:** The immunosuppressive TME of solid tumours, rich in regulatory T-cells, myeloid-derived suppressor cells, and inhibitory cytokines, limits CAR T-cell infiltration and persistence. Overcoming these barriers requires engineering CAR T-cells to resist immunosuppression and improve trafficking to tumour sites [29].
2. **Antigen Heterogeneity:** Unlike hematologic cancers, solid tumours exhibit heterogeneous antigen expression, increasing the risk of tumour escape. Dual-targeting CAR T-cells or universal CARs capable of recognizing multiple antigens are being developed to address this limitation [30].
3. **Physical Barriers:** Dense stroma and fibrotic tissues in solid tumours impede CAR T-cell penetration. Strategies such as co-administration of enzymes that degrade the extracellular matrix are under investigation to enhance intratumoural delivery [31].

Breakthroughs in Solid Tumour CAR T-Cell Therapy

Recent innovations have shown promise in expanding CAR T-cell efficacy in solid tumours:

- **Armored CAR T-Cells:** These are engineered to secrete pro-inflammatory cytokines or checkpoint inhibitors, countering the immunosuppressive TME and enhancing antitumour activity [27].
- **Localized CAR T-Cell Delivery:** Intratumoural injections reduce systemic toxicities and improve tumour-specific effects [32].
- **Oncolytic Virus-Enhanced CAR T-Cells:** Combining CAR T-cells with oncolytic viruses that selectively infect and destroy tumour cells enhances CAR T-cell infiltration and activation.

Clinical trials targeting solid tumour antigens like HER2, GD2, and mesothelin are demonstrating encouraging early results, signaling the potential to broaden CAR T-cell therapy's impact beyond hematologic malignancies.

5.2 Combining CAR T-Cells with Other Therapies

Combining CAR T-cells with other therapeutic modalities is emerging as a powerful strategy to enhance efficacy and overcome resistance in cancer treatment [32]. Synergies between CAR T-cells and therapies like checkpoint inhibitors or oncolytic viruses provide complementary mechanisms to improve outcomes.

Checkpoint Inhibitors

Checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, block immune checkpoints that suppress T-cell activity. When combined with CAR T-cells, these inhibitors help sustain CAR T-cell function within the immunosuppressive TME. Preclinical studies demonstrate that anti-PD-1 antibodies enhance CAR T-cell persistence and antitumour activity, particularly in solid tumours [33].

Oncolytic Viruses

Oncolytic viruses selectively infect and lyse tumour cells while sparing normal tissues. This process releases tumour-associated antigens, amplifying the immune response. Oncolytic viruses also remodel the TME, making it more conducive to CAR T-cell activity [31]. Trials combining oncolytic viruses like talimogene laherparepvec [T-VEC] with CAR T-cells have shown increased tumour infiltration and enhanced efficacy in resistant cancers [34].

Other Combination Strategies

- **Cytokine Modulation:** Administering cytokines such as IL-7 or IL-15 alongside CAR T-cells boosts their expansion and persistence in vivo.
- **Radiation Therapy:** Radiation increases tumour antigen presentation, sensitizing tumours to CAR T-cell attacks [32].
- **Immune Agonists:** Agents like OX40 or 4-1BB agonists stimulate T-cell activity and synergize with CAR T-cell therapies [35].

These combination approaches are advancing through clinical trials and hold promise for overcoming resistance and expanding CAR T-cell applications across diverse cancer types.

5.3 Personalized CAR T-Cell Therapy

Personalizing CAR T-cell therapy through molecular profiling and advanced manufacturing represents the forefront of cancer immunotherapy [44]. This approach tailors CAR T-cell constructs to individual tumour characteristics, enhancing specificity and efficacy.

Molecular Profiling for Target Selection

Advances in next-generation sequencing [NGS] and single-cell RNA sequencing enable detailed tumour profiling to identify patient-specific antigens and mutations. This data guides the design of CAR T-cells optimized for the unique molecular landscape of each tumour [36]. For instance, neoantigen-specific CARs target mutations exclusive to tumour cells, reducing off-tumour toxicity.

Custom Manufacturing

Customized manufacturing workflows integrate molecular profiling data to produce CAR T-cells tailored to each patient. Innovations like CRISPR-Cas9 editing and synthetic biology accelerate the development of personalized CAR T-cells with enhanced functionality and safety [37]. Automation in manufacturing further improves scalability and reduces production times.

By integrating cutting-edge technologies, personalized CAR T-cell therapy offers a promising pathway to overcome tumour heterogeneity and resistance, ensuring that treatments are both effective and safe for each individual patient.

6. REAL-WORLD OUTCOMES AND CASE STUDIES

6.1 Real-World Effectiveness of CAR T-Cell Therapy

Real-world data [RWD] provides critical insights into the effectiveness of CAR T-cell therapy outside controlled clinical trial settings. While clinical trials demonstrate remarkable efficacy, translating these outcomes into broader, real-world practice presents unique challenges and opportunities.

Outcomes in Diverse Patient Populations

Real-world studies indicate that CAR T-cell therapy achieves outcomes comparable to those observed in clinical trials for many patients. For example, a post-approval study of axicabtagene ciloleucel in refractory diffuse large B-cell lymphoma [DLBCL] reported overall response rates [ORR] of 74%, closely mirroring the ZUMA-1 trial results [38]. However, real-world cohorts include more diverse patient populations, such as older individuals and those with significant comorbidities, who are often excluded from trials. These populations sometimes experience higher rates of toxicities, such as CRS, or lower treatment efficacy due to baseline health conditions [39].

Comparisons with Clinical Trial Results

Clinical trial settings benefit from stringent eligibility criteria, optimal infrastructure, and experienced clinical teams. In contrast, real-world settings often involve variability in provider expertise, resource availability, and patient adherence [37]. Despite these challenges, RWD confirms that CAR T-cell therapy offers durable remissions in heavily pretreated patients, albeit with slightly lower progression-free survival [PFS] rates than trials [40].

Real-world data highlights the importance of expanding access to CAR T-cell therapy, tailoring protocols for broader populations, and investing in post-treatment monitoring to replicate trial-level outcomes in diverse healthcare settings.

6.2 Case Studies: Success Stories

Case studies of exceptional outcomes underscore the transformative potential of CAR T-cell therapy in patients with advanced malignancies [42]. These examples illustrate the therapy's ability to deliver long-lasting remissions, even in cases where other treatments have failed.

Case 1: Complete Remission in Refractory DLBCL

A 56-year-old patient with refractory DLBCL, who had relapsed after two lines of chemotherapy, underwent CAR T-cell therapy with axicabtagene ciloleucel. Despite a high tumour burden and poor prognosis, the patient achieved complete remission within three months of infusion [50]. Follow-up PET scans at one and two years confirmed sustained remission, showcasing the therapy's durability and curative potential in select cases [41].

Case 2: Pediatric ALL Patient Achieving Long-Term Survival

A 9-year-old child with relapsed acute lymphoblastic leukemia [ALL] was treated with tisagenlecleucel after exhausting conventional options. The therapy induced complete remission within 30 days, and the patient remained disease-free for over five years. This case highlights CAR T-cell therapy's effectiveness in pediatric populations, where long-term survival significantly impacts quality of life [42].

Case 3: Promising Results in Solid Tumours

While CAR T-cell therapy is primarily successful in hematologic malignancies, a recent case involving a patient with advanced mesothelioma treated with mesothelin-targeted CAR T-cells demonstrated partial tumour regression and improved quality of life [49]. Though not curative, this outcome illustrates the expanding potential of CAR T-cell therapy in solid tumours [43].

These success stories validate the potential of CAR T-cell therapy to transform outcomes across diverse cancers and patient demographics.

6.3 Challenges Highlighted by Real-World Data

Despite its successes, **real-world data [RWD]** also highlights several challenges associated with CAR T-cell therapy, emphasizing areas for improvement in future implementation.

Discrepancies Between Clinical Trials and Practice

Clinical trials often select ideal candidates—those with good performance status, limited comorbidities, and manageable disease burdens. Real-world settings, however, encompass more heterogeneous populations [49]. For instance, older patients or those with significant preexisting conditions may experience higher rates of toxicities such as CRS and ICANS [44]. Moreover, logistical challenges, such as delays in manufacturing and treatment initiation, are more pronounced in real-world practice, potentially impacting outcomes.

A study comparing real-world outcomes of axicabtagene ciloleucel in refractory DLBCL revealed slightly lower response rates and progression-free survival [PFS] than observed in clinical trials. For example, PFS at 12 months was 50% in real-world cohorts versus 60% in the ZUMA-1 trial [45]. These discrepancies underscore the need for tailored management protocols and infrastructure improvements.

Lessons Learned for Future Implementation

1. **Enhanced Toxicity Management:** High rates of CRS and ICANS in real-world settings necessitate widespread training in early identification and management of these toxicities. Expanding access to IL-6 inhibitors, such as tocilizumab, and establishing intensive care protocols are essential [48].
2. **Streamlined Manufacturing:** Reducing delays in CAR T-cell production through automation or off-the-shelf CAR T-cell products can improve treatment accessibility and effectiveness [46].
3. **Post-Treatment Monitoring:** Real-world data emphasize the need for robust follow-up care to manage late toxicities and monitor long-term remission [47].
4. **Infrastructure Investments:** Increasing the number of specialized treatment centres and equipping community hospitals with CAR T-cell capabilities are critical to addressing disparities in access [50] [46].

By addressing these challenges, the broader adoption of CAR T-cell therapy can be realized, ensuring its life-saving benefits reach a greater number of patients.

7. RECOMMENDATIONS AND CONCLUSION

7.1 Recommendations for Clinicians

To maximize the benefits of CAR T-cell therapy and address its associated challenges, clinicians play a pivotal role in managing toxicities, ensuring safety, and improving patient access to treatment.

Managing Toxicities

Proactive management of toxicities, such as CRS and ICANS, is critical for improving patient outcomes. Clinicians should:

1. **Implement Early Detection Protocols:** Regular monitoring of biomarkers, such as IL-6 levels, and the use of scoring systems like the ICE score can help identify toxicities at early stages.
2. **Standardize Intervention Strategies:** Establish protocols for the timely administration of IL-6 inhibitors, corticosteroids, and anticonvulsants, tailored to toxicity severity. Training multidisciplinary teams in toxicity management ensures consistent care delivery.
3. **Focus on Personalized Care:** Recognize patient-specific factors, such as age, comorbidities, and tumour burden, to optimize dosing and predict toxicity risks.

Addressing Patient Concerns

Clinicians must actively address patient concerns related to accessibility and affordability. Key strategies include:

1. **Transparent Communication:** Clearly explain the costs, potential toxicities, and expected outcomes of CAR T-cell therapy to empower patients in decision-making.
2. **Support Navigation of Financial Resources:** Guide patients toward financial assistance programs, insurance coverage options, and clinical trials to reduce treatment-related burdens.
3. **Enhance Follow-Up Care:** Establish long-term monitoring protocols to address late-onset toxicities and improve the overall treatment experience.

By integrating these practices into routine care, clinicians can ensure the safe and effective delivery of CAR T-cell therapy while addressing patient concerns.

7.2 Policy Recommendations for Accessibility

To expand the reach of CAR T-cell therapy, policy interventions must focus on reducing costs, increasing coverage, and incentivizing infrastructure development.

Reducing Treatment Costs

Policymakers can implement strategies to alleviate the high costs associated with CAR T-cell therapy:

1. **Subsidized Manufacturing:** Support the development of centralized manufacturing hubs to streamline production and achieve economies of scale.
2. **Outcomes-Based Pricing Models:** Encourage agreements between manufacturers and payers that link therapy costs to patient outcomes. This approach balances innovation with cost-effectiveness.

3. **Tax Incentives for Biopharma Investment:** Offer tax breaks to pharmaceutical companies investing in CAR T-cell research, development, and production.

Expanding Coverage

Expanding insurance coverage and reimbursement policies is essential for increasing accessibility:

1. **Comprehensive Insurance Plans:** Mandate inclusion of CAR T-cell therapy in both public and private insurance policies, ensuring equitable access for patients.
2. **Global Harmonization of Policies:** Facilitate international collaborations to align regulatory and reimbursement frameworks, particularly in low- and middle-income countries.

Incentivizing Infrastructure Development

To address geographical disparities in access to CAR T-cell therapy, policymakers should:

1. **Support Treatment Center Expansion:** Provide funding for the establishment of new treatment centres, especially in underserved regions.
2. **Promote Training Programs:** Allocate resources for clinician training and certification programs to expand the pool of skilled professionals.
3. **Encourage Public-Private Partnerships:** Foster collaborations between governments, academic institutions, and private entities to accelerate infrastructure development and enhance access.

These policies will lay the foundation for equitable, sustainable, and widespread access to CAR T-cell therapy.

7.3 Conclusion and Future Directions

CAR T-cell therapy has revolutionized cancer treatment, offering curative potential for patients with relapsed or refractory malignancies. However, its full impact is limited by challenges such as high costs, manufacturing bottlenecks, and toxicities. Addressing these barriers requires coordinated efforts among clinicians, policymakers, and industry stakeholders.

Key Insights

1. **Clinical Implementation:** Effective management of toxicities and individualized care protocols are critical for ensuring treatment safety and efficacy.
2. **Infrastructure and Access:** Expanding treatment centres, investing in workforce training, and integrating telemedicine into follow-up care are essential for improving accessibility.
3. **Cost Reduction:** Innovations such as automation in manufacturing, outcomes-based pricing models, and allogeneic CAR T-cell products hold promise for reducing costs and scaling production.

Future Research Directions

Looking ahead, research must focus on:

1. **Advancing Solid Tumour Therapies:** Developing CAR T-cell constructs that overcome the unique challenges of the tumour microenvironment in solid cancers.
2. **Combination Strategies:** Exploring synergies between CAR T-cells and other therapies, such as checkpoint inhibitors and oncolytic viruses, to enhance efficacy.
3. **Personalized Medicine:** Leveraging molecular profiling and CRISPR-based technologies to tailor therapies to individual patients.

By addressing these areas, the next generation of CAR T-cell therapies can overcome current limitations, expanding their transformative potential to a broader patient population. Collaborative efforts across all sectors will ensure that CAR T-cell therapy continues to evolve as a cornerstone of precision oncology.

REFERENCE

1. June CH, O'Connor RS, Kawalekar OU, CAR T cell immunotherapy for human cancer. *Science*. 2018;359(6382):1361-1365. https://doi.org/10.1126/science.aar6711
2. Schuster SJ, Bishop MR, Tam CS, Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. *N Engl J Med*. 2019;380(1):45-56. https://doi.org/10.1056/NEJMoa1804980
3. Maude SL, Laetsch TW, Buechner J, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N Engl J Med*. 2018;378(5):439-448. https://doi.org/10.1056/NEJMoa1709866

4. Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. *Cancer Discov*. 2018;8(10):1219-1226. https://doi.org/10.1158/2159-8290.CD-18-0442
5. Neelapu SS, Tummala S, Kebriaei P, Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. *Nat Rev Clin Oncol*. 2018;15(1):47-62. https://doi.org/10.1038/nrclinonc.2017.148
6. Mullard A. FDA approval brings first gene therapy to the United States. *Nat Rev Drug Discov*. 2017;16(10):669. https://doi.org/10.1038/nrd.2017.184
7. Sterner RC, Sterner RM. CAR T-cell therapy: current limitations and potential strategies. *Blood Cancer J*. 2021;11(4):69. https://doi.org/10.1038/s41408-021-00459-7
8. Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. *Nat Rev Clin Oncol*. 2018;15(1):31-46. https://doi.org/10.1038/nrclinonc.2017.128
9. Locke FL, Ghobadi A, Jacobson CA, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. *Lancet Oncol*. 2019;20(1):31-42. https://doi.org/10.1016/S1470-2045(18)30864-7
10. Jain M, Davila ML. Concise review: emerging principles from the clinical application of chimeric antigen receptor T cell therapies for cancer. *Stem Cells Transl Med*. 2018;7(4):354-363. https://doi.org/10.1002/sctm.17-0280
11. Lee DW, Santomasso BD, Locke FL, ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. *Biol Blood Marrow Transplant*. 2019;25(4):625-638. https://doi.org/10.1016/j.bbmt.2018.12.758
12. Le RQ, Li L, Yuan W, FDA approval summary: tocilizumab for the treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. *Oncologist*. 2018;23(8):943-947. https://doi.org/10.1634/theoncologist.2018-0028
13. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T-cell immunotherapy. *Blood*. 2016;127(26):3321-3330. https://doi.org/10.1182/blood-2016-04-703751
14. Porter DL, Hwang WT, Frey NV, Chimeric antigen receptor T cells in patients with relapsed or refractory chronic lymphoid leukemia. *N Engl J Med*. 2015;373(11):1016-1027. https://doi.org/10.1056/NEJMoa1505747
15. Gust J, Hay KA, Hanafi L-A, Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. *Cancer Discov*. 2017;7(12):1404-1419. https://doi.org/10.1158/2159-8290.CD-17-0698
16. Santomasso BD, Bachier CR, Westin JR, The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. *Am Soc Clin Oncol Educ Book*. 2019;39:433-444. https://doi.org/10.1200/EDBK_240828
17. Hill JA, Li D, Hay KA, Cytokine release syndrome in CAR T-cell therapy: key principles for predicting, preventing, and treating. *Blood*. 2020;136(2):188-195. https://doi.org/10.1182/blood.2020004828
18. Locke FL, Ghobadi A, Jacobson CA, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. *Lancet Oncol*. 2019;20(1):31-42. https://doi.org/10.1016/S1470-2045(18)30864-7
19. Miklos D, Martin T, Wang J, Managing infections in CAR T-cell therapy. *Hematol Oncol Clin North Am*. 2020;34(2):281-297. https://doi.org/10.1016/j.hoc.2020.02.001
20. Fried S, Avigdor A, Bielorai B, Early and late hematologic toxicity following CD19 CAR-T cells. *Haematologica*. 2019;104(4):697-707. https://doi.org/10.3324/haematol.2018.206045
21. Park JH, Rivière I, Gonen M, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. *N Engl J Med*. 2018;378(5):449-459. https://doi.org/10.1056/NEJMoa1709919
22. Zhou X, Dotti G, Krance RA, Inducible caspase 9 for the reduction of severe toxicities in CAR T-cell therapy. *Nat Med*. 2019;25(4):703-714. https://doi.org/10.1038/s41591-019-0390-0
23. Yeung JT, Fedele C, Dong S, Hypoxia-responsive CAR T-cells: Enhancing tumor specificity. *Mol Ther*. 2020;28(8):1801-1812. https://doi.org/10.1016/j.ymthe.2020.05.014
24. Hay KA, Hanafi L-A, Li D, Risk-adapted therapy for CAR T-cell toxicities. *Blood*. 2017;130(4):453-462. https://doi.org/10.1182/blood-2017-01-761726
25. Porter DL, Frey NV, Wood PA, Fractionated CAR T-cell dosing: Safety and efficacy outcomes. *J Clin Oncol*. 2018;36(16):1619-1629. https://doi.org/10.1200/JCO.2018.36.16.1619
26. Brown CE, Mackall CL. CAR T-cell delivery for solid tumors: Localized strategies. *Nat Rev Clin Oncol*. 2019;16(1):47-56. https://doi.org/10.1038/s41571-018-0113-2

27. Neelapu SS, Tummala S, Kebriaei P, Cytokine release syndrome: Biomarkers and management. *Nat Rev Clin Oncol*. 2018;15(1):47-62. https://doi.org/10.1038/nrclinonc.2017.148

28. Chukwunweike JN, Pelumi O, Ibrahim OA, 2024.Leveraging AI and Deep Learning in Predictive Genomics for MPOX Virus Research using MATLAB. DOI: 10.7753/IJCATR1309.1001

29. Hay KA, Turtle CJ. CAR T-cell therapy: A new era in cancer treatment. *Hematol Oncol Clin North Am*. 2020;34(4):1017-1039. https://doi.org/10.1016/j.hoc.2020.02.010

30. Locke FL, Ghobadi A, Jacobson CA, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1). *Lancet Oncol*. 2019;20(1):31-42. https://doi.org/10.1016/S1470-2045(18)30864-7

31. Okusi O. Leveraging AI and machine learning for the protection of critical national infrastructure. Asian Journal of Research in Computer Science. 2024 Sep 27;17(10):1-1. http://dx.doi.org/10.9734/ajrcos/2024/v17i10505

32. Mullard A. Pricing pressure on CAR T-cell therapies. *Nat Rev Drug Discov*. 2019;18(12):853-855. https://doi.org/10.1038/d41573-019-00036-y

33. Garrison LP, Neumann PJ, Willke RJ. Value-based pricing for emerging oncology therapies: CAR T-cells as a case study. *J Clin Oncol*. 2018;36(7):670-676. https://doi.org/10.1200/JCO.2017.74.2092

34. Maus MV, Levine BL. The evolution of CAR T-cell manufacturing: Current status and future strategies. *Blood*. 2016;127(26):3324-3331. https://doi.org/10.1182/blood-2016-03-708073

35. Srivastava S, Riddell SR. Engineering CAR T cells: Challenges and opportunities. *Nat Rev Immunol*. 2015;15(10):563-576. https://doi.org/10.1038/nri3894

36. Depil S, Duchateau P, Grupp SA, Off-the-shelf CAR T cells: Development and challenges. *Nat Rev Drug Discov*. 2020;19(3):185-199. https://doi.org/10.1038/s41573-019-0051-2

37. Miklos D, Martin T, Wang J, Expanding CAR T-cell therapy access: Strategies and challenges. *Hematol Oncol Clin North Am*. 2020;34(2):281-297. https://doi.org/10.1016/j.hoc.2020.02.001

38. Dahiya S, Wong E, Park JH, Training programs for CAR T-cell therapy administration. *JCO Oncol Pract*. 2021;17(6) . https://doi.org/10.1200/OP.21.00234

39. Jain MD, Zhao H, Wang X, Telemedicine in CAR T-cell therapy follow-up. *JCO Clin Cancer Inform*. 2020;4:919-930. https://doi.org/10.1200/CCI.20.00011

40. Green MR, Rodig S, Juszczynski P, Molecular profiling to advance precision medicine in hematologic malignancies. *Nat Rev Clin Oncol*. 2018;15(8):529-547. https://doi.org/10.1038/s41571-018-0043-z

41. Locke FL, Ghobadi A, Jacobson CA, Real-world outcomes of axicabtagene ciloleucel in large B-cell lymphoma. *J Clin Oncol*. 2020;38(6):370-380. https://doi.org/10.1200/JCO.19.02191

42. Ajiboye Festus Segun. Advances in personalized medical therapeutics: Leveraging genomics for targeted treatments [Internet]. Department of Bioinformatics, Luddy School of Informatics and Engineering; [cited 2024 Nov 15]. Available from: https://doi.org/10.55248/gengpi.5.1024.2905

43. Hay KA, Turtle CJ. Toxicities of CAR T-cell therapy in real-world settings. *Nat Rev Clin Oncol*. 2019;16(1):47-56. https://doi.org/10.1038/s41571-018-0113-2

44. Schuster SJ, Tam CS, Borchmann P, Long-term follow-up of CD19 CAR therapy in DLBCL. *Blood*. 2021;137(3):367-376. https://doi.org/10.1182/blood.2020007240

45. Neelapu SS, Locke FL, Bartlett NL, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *N Engl J Med*. 2017;377(26):2531-2544. https://doi.org/10.1056/NEJMoa1707447

46. Maude SL, Laetsch TW, Buechner J, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N Engl J Med*. 2018;378(5):439-448. https://doi.org/10.1056/NEJMoa1709866

47. Beatty GL, O'Hara M. Mesothelin-targeted CAR T cells in solid tumors: Early clinical experience. *Clin Cancer Res*. 2020;26(6):1325-1331. https://doi.org/10.1158/1078-0432.CCR-19-2239

48. Shallon Asiimire, Baton Rouge, Fechi George Odocha, Friday Anwansedo, Oluwaseun Rafiu Adesanya. Sustainable economic growth through artificial intelligence-driven tax frameworks nexus on enhancing business efficiency and prosperity: An appraisal. International Journal of Latest Technology in Engineering, Management & Applied Science. 2024;13(9):44-52. Available from: https://doi.org/10.51583/IJLTEMAS.2024.130904

49. Gust J, Hay KA, Hanafi L-A, Endothelial activation and blood-brain barrier disruption in neurotoxicity after CD19 CAR-T therapy. *Cancer Discov*. 2017;7(12):1404-1419. https://doi.org/10.1158/2159-8290.CD-17-0698

50. Jain MD, Zhao H, Wang X, Comparing clinical trial and real-world outcomes of CAR T-cell therapy. *J Clin Oncol*. 2020;38(15). https://doi.org/10.1200/JCO.2020.38.15_suppl.e19505